256 related articles for article (PubMed ID: 34753908)
1. The chemotherapeutic CX-5461 primarily targets TOP2B and exhibits selective activity in high-risk neuroblastoma.
Pan M; Wright WC; Chapple RH; Zubair A; Sandhu M; Batchelder JE; Huddle BC; Low J; Blankenship KB; Wang Y; Gordon B; Archer P; Brady SW; Natarajan S; Posgai MJ; Schuetz J; Miller D; Kalathur R; Chen S; Connelly JP; Babu MM; Dyer MA; Pruett-Miller SM; Freeman BB; Chen T; Godley LA; Blanchard SC; Stewart E; Easton J; Geeleher P
Nat Commun; 2021 Nov; 12(1):6468. PubMed ID: 34753908
[TBL] [Abstract][Full Text] [Related]
2. Down-regulation of MYCN protein by CX-5461 leads to neuroblastoma tumor growth suppression.
Taylor JS; Zeki J; Ornell K; Coburn J; Shimada H; Ikegaki N; Chiu B
J Pediatr Surg; 2019 Jun; 54(6):1192-1197. PubMed ID: 30879743
[TBL] [Abstract][Full Text] [Related]
3. The primary mechanism of cytotoxicity of the chemotherapeutic agent CX-5461 is topoisomerase II poisoning.
Bruno PM; Lu M; Dennis KA; Inam H; Moore CJ; Sheehe J; Elledge SJ; Hemann MT; Pritchard JR
Proc Natl Acad Sci U S A; 2020 Feb; 117(8):4053-4060. PubMed ID: 32041867
[TBL] [Abstract][Full Text] [Related]
4. TOP2B Is Required to Maintain the Adrenergic Neural Phenotype and for ATRA-Induced Differentiation of SH-SY5Y Neuroblastoma Cells.
Khazeem MM; Casement JW; Schlossmacher G; Kenneth NS; Sumbung NK; Chan JYT; McGow JF; Cowell IG; Austin CA
Mol Neurobiol; 2022 Oct; 59(10):5987-6008. PubMed ID: 35831557
[TBL] [Abstract][Full Text] [Related]
5. Targeting RNA polymerase I with an oral small molecule CX-5461 inhibits ribosomal RNA synthesis and solid tumor growth.
Drygin D; Lin A; Bliesath J; Ho CB; O'Brien SE; Proffitt C; Omori M; Haddach M; Schwaebe MK; Siddiqui-Jain A; Streiner N; Quin JE; Sanij E; Bywater MJ; Hannan RD; Ryckman D; Anderes K; Rice WG
Cancer Res; 2011 Feb; 71(4):1418-30. PubMed ID: 21159662
[TBL] [Abstract][Full Text] [Related]
6. Transient rRNA synthesis inhibition with CX-5461 is sufficient to elicit growth arrest and cell death in acute lymphoblastic leukemia cells.
Negi SS; Brown P
Oncotarget; 2015 Oct; 6(33):34846-58. PubMed ID: 26472108
[TBL] [Abstract][Full Text] [Related]
7. The RNA polymerase I transcription inhibitor CX-5461 cooperates with topoisomerase 1 inhibition by enhancing the DNA damage response in homologous recombination-proficient high-grade serous ovarian cancer.
Yan S; Xuan J; Brajanovski N; Tancock MRC; Madhamshettiwar PB; Simpson KJ; Ellis S; Kang J; Cullinane C; Sheppard KE; Hannan KM; Hannan RD; Sanij E; Pearson RB; Chan KT
Br J Cancer; 2021 Feb; 124(3):616-627. PubMed ID: 33173151
[TBL] [Abstract][Full Text] [Related]
8. PI3K inhibitors prime neuroblastoma cells for chemotherapy by shifting the balance towards pro-apoptotic Bcl-2 proteins and enhanced mitochondrial apoptosis.
Bender A; Opel D; Naumann I; Kappler R; Friedman L; von Schweinitz D; Debatin KM; Fulda S
Oncogene; 2011 Jan; 30(4):494-503. PubMed ID: 20856197
[TBL] [Abstract][Full Text] [Related]
9. Anti-GD2-IRDye800CW as a targeted probe for fluorescence-guided surgery in neuroblastoma.
Wellens LM; Deken MM; Sier CFM; Johnson HR; de la Jara Ortiz F; Bhairosingh SS; Houvast RD; Kholosy WM; Baart VM; Pieters AMMJ; de Krijger RR; Molenaar JJ; Wehrens EJ; Dekkers JF; Wijnen MHWA; Vahrmeijer AL; Rios AC
Sci Rep; 2020 Oct; 10(1):17667. PubMed ID: 33077751
[TBL] [Abstract][Full Text] [Related]
10. ABCC multidrug transporters in childhood neuroblastoma: clinical and biological effects independent of cytotoxic drug efflux.
Henderson MJ; Haber M; Porro A; Munoz MA; Iraci N; Xue C; Murray J; Flemming CL; Smith J; Fletcher JI; Gherardi S; Kwek CK; Russell AJ; Valli E; London WB; Buxton AB; Ashton LJ; Sartorelli AC; Cohn SL; Schwab M; Marshall GM; Perini G; Norris MD
J Natl Cancer Inst; 2011 Aug; 103(16):1236-51. PubMed ID: 21799180
[TBL] [Abstract][Full Text] [Related]
11. Targeting tachykinin receptors in neuroblastoma.
Henssen AG; Odersky A; Szymansky A; Seiler M; Althoff K; Beckers A; Speleman F; Schäfers S; De Preter K; Astrahanseff K; Struck J; Schramm A; Eggert A; Bergmann A; Schulte JH
Oncotarget; 2017 Jan; 8(1):430-443. PubMed ID: 27888795
[TBL] [Abstract][Full Text] [Related]
12. Inhibitors of ribosome biogenesis repress the growth of MYCN-amplified neuroblastoma.
Hald ØH; Olsen L; Gallo-Oller G; Elfman LHM; Løkke C; Kogner P; Sveinbjörnsson B; Flægstad T; Johnsen JI; Einvik C
Oncogene; 2019 Apr; 38(15):2800-2813. PubMed ID: 30542116
[TBL] [Abstract][Full Text] [Related]
13. Chromatin remodelling at the topoisomerase II-beta promoter is associated with enhanced sensitivity to etoposide in human neuroblastoma cell lines.
Das CM; Zage PE; Taylor P; Aguilera D; Wolff JE; Lee D; Gopalakrishnan V
Eur J Cancer; 2010 Oct; 46(15):2771-80. PubMed ID: 20886683
[TBL] [Abstract][Full Text] [Related]
14. Synergistic cytotoxic effects of bortezomib and CK2 inhibitor CX-4945 in acute lymphoblastic leukemia: turning off the prosurvival ER chaperone BIP/Grp78 and turning on the pro-apoptotic NF-κB.
Buontempo F; Orsini E; Lonetti A; Cappellini A; Chiarini F; Evangelisti C; Evangelisti C; Melchionda F; Pession A; Bertaina A; Locatelli F; Bertacchini J; Neri LM; McCubrey JA; Martelli AM
Oncotarget; 2016 Jan; 7(2):1323-40. PubMed ID: 26593250
[TBL] [Abstract][Full Text] [Related]
15. Targeting histone deacetylases (HDACs) and Wee1 for treating high-risk neuroblastoma.
Hanmod SS; Wang G; Edwards H; Buck SA; Ge Y; Taub JW; Wang Z
Pediatr Blood Cancer; 2015 Jan; 62(1):52-9. PubMed ID: 25308916
[TBL] [Abstract][Full Text] [Related]
16. Celecoxib prevents neuroblastoma tumor development and potentiates the effect of chemotherapeutic drugs in vitro and in vivo.
Ponthan F; Wickström M; Gleissman H; Fuskevåg OM; Segerström L; Sveinbjörnsson B; Redfern CP; Eksborg S; Kogner P; Johnsen JI
Clin Cancer Res; 2007 Feb; 13(3):1036-44. PubMed ID: 17289900
[TBL] [Abstract][Full Text] [Related]
17. Down-regulation of insulin-like growth factor I receptor activity by NVP-AEW541 has an antitumor effect on neuroblastoma cells in vitro and in vivo.
Tanno B; Mancini C; Vitali R; Mancuso M; McDowell HP; Dominici C; Raschellà G
Clin Cancer Res; 2006 Nov; 12(22):6772-80. PubMed ID: 17121898
[TBL] [Abstract][Full Text] [Related]
18. Effect of imatinib mesylate on neuroblastoma tumorigenesis and vascular endothelial growth factor expression.
Beppu K; Jaboine J; Merchant MS; Mackall CL; Thiele CJ
J Natl Cancer Inst; 2004 Jan; 96(1):46-55. PubMed ID: 14709738
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic Targeting of RNA Polymerase I With the Small-Molecule CX-5461 for Prevention of Arterial Injury-Induced Neointimal Hyperplasia.
Ye Q; Pang S; Zhang W; Guo X; Wang J; Zhang Y; Liu Y; Wu X; Jiang F
Arterioscler Thromb Vasc Biol; 2017 Mar; 37(3):476-484. PubMed ID: 28062495
[TBL] [Abstract][Full Text] [Related]
20. Enhanced cell cycle perturbation and apoptosis mediate the synergistic effects of ST1926 and ATRA in neuroblastoma preclinical models.
Di Francesco AM; Ubezio P; Torella AR; Meco D; Pierri F; Barone G; Cusano G; Pisano C; D'Incalci M; Riccardi R
Invest New Drugs; 2012 Aug; 30(4):1319-30. PubMed ID: 21633925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
